SLU-PP-332 ! Dieser Fatburner macht dich SHREDDED OHNE CARDIO!

Summary

The video discusses SLU-PP-332, a synthetic small molecule presented as a possible “exercise mimetic”—a compound intended to trigger some metabolic effects associated with endurance exercise. The hosts stress that the evidence is still limited and largely preclinical; the video’s title claim that it can make someone shredded without cardio is not established by the evidence described.

Scientific Concepts and Reported Findings

• What it is: SLU-PP-332 is described as a small molecule, not a peptide. It is said to activate estrogen-related receptors (ERRs), especially ERRα. Despite their name, these receptors are described as orphan receptors and are distinct from the body’s conventional estrogen receptors.
• Metabolic pathways: The discussion links ERR activation with PGC-1α, TFAM, and mitochondrial biogenesis—the formation of mitochondria involved in cellular energy production. The hosts suggest these pathways may contribute to changes in endurance-related metabolism.
• Potential exercise-mimetic effects: Based mainly on animal research, the compound is said to increase fat use and alter glucose use at rest, with reported effects on endurance-related measures such as VO₂ max. These are not presented as established outcomes in humans.
• Body fat and lipid claims: Mouse studies are described as showing reduced fat mass, less fat gain during calorie surplus, and improved blood lipid measures. One reported animal result was a 12% reduction in body weight. The hosts also recount striking improvements in blood lipids from a few people’s blood tests, but these are anecdotes, not controlled human evidence.
• Possible trade-offs for strength training: The discussion raises concerns that increased fat oxidation and reduced muscle glycogen could affect high-intensity performance. It also mentions increased slow oxidative muscle fibers in mice, which could theoretically be less favorable for bodybuilding-style hypertrophy. The actual impact on human muscle growth is unknown.
• Other proposed health effects: Heart, kidney, liver—including fatty liver—and possible cognitive or addiction-related effects are mentioned as areas of interest. These claims are described as preliminary, with much of the evidence coming from animal studies.
• Safety and limitations: The hosts acknowledge that there is little human research and no established long-term safety data. They mention restlessness, difficulty sleeping, sweating, and unusually strong workout “pumps” as reported side effects, but these reports are anecdotal. The video also discusses doses used by people online; it does not establish a validated or safe human dose.

Takeaway

SLU-PP-332 is an experimental compound with intriguing proposed metabolic effects, but the discussion does not establish that it safely causes substantial fat loss or replaces exercise in humans. The animal findings, personal reports, and speculative benefits should be distinguished from proven clinical results; long-term effects and appropriate human dosing remain unknown.

Researchers and Sources Mentioned

• Michel Queen — guest discussing the compound; no research role is specified in the subtitles.
• Tony Huge — mentioned as an early promoter of SLU-PP-332.
• Unspecified mouse studies, including a study from 2024 and studies described as appearing in 2025; the subtitles do not identify authors or provide paper titles.
• Anecdotal blood-test reports and reports from athletes or users; these are not identified as formal research sources.